The governor won praise around the state for his early efforts to combat the coronavirus, but as the crisis wore on and President Donald Trump played down the threat, Ohio Republicans began to grow restless with DeWine’s stance, and concerns for his reelection campaign in 2022 are rising.
As coronavirus cases surge, state officials can’t afford to wait for a new president to take office before taking action. But some governors’ initiatives seem to be little more than policy tweaks or symbolic gestures.
Parents are turning to spooky scavenger hunts, pumpkin-carving and movie nights as alternatives to trick-or-treating. Health professionals have their own advice on how to safely celebrate Halloween during the pandemic.
Public health officials are confronting growing pressure — and threats — across the country as the backlash to the coronavirus response continues. At least 27 state and local health leaders have resigned, retired or been fired since April across 13 states.
A public hospital in Cleveland has been trying to keep COVID patients out of its beds. It tried a number of innovations for developing better communication — even better relationships — with patients. Officials think this groundwork helped keep the outbreak at bay — and should be the new business model going forward.
The proposal being weighed by federal officials would allow employers and insurers to decide that drug companies’ assistance doesn’t count toward their members’ deductible or out-of-pocket maximum spending limits. If plans opted for that approach, only payments made by patients themselves would be included in the calculation toward reaching those limits.
The coronavirus outbreak has forced millions out of work and the federal-state health program for low-income people could face unprecedented strains as many states don’t necessarily have the resources or systems in place to meet the demand.
Maryland, Ohio and others are reporting only positive tests, which skews tracking and an understanding of how the virus spreads.
House Democrats start legislative work on House Speaker Nancy Pelosi’s prescription drug pricing bill; health is again a featured player in the Democratic presidential candidate debate; and courts around the country hold up President Donald Trump’s health agenda. This week, Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists recommend their favorite health stories of the week.
The reasons behind one particular shortage of a therapy known as IVIG are complicated, stemming from increased demand and the medication’s long production window.